Melissa Baird Sells 67,687 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $34.84, for a total transaction of $2,358,215.08. Following the completion of the transaction, the chief operating officer now directly owns 751,243 shares of the company’s stock, valued at approximately $26,173,306.12. The trade was a 8.27 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Wednesday, February 12th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.71, for a total value of $3,026,285.77.
• On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.35, for a total transaction of $1,986,613.45.

Hims & Hers Health Stock Performance

Shares of HIMS traded down $1.40 on Thursday, hitting $31.96. 15,194,343 shares of the stock traded hands, compared to its average volume of 13,990,192. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The company has a market capitalization of $7.10 billion, a PE ratio of 72.63 and a beta of 1.37. The business has a 50 day simple moving average of $39.77 and a 200 day simple moving average of $29.25.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of recent analyst reports. Bank of America boosted their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research report on Tuesday, March 18th. Citigroup restated a “sell” rating and issued a $27.00 target price on shares of Hims & Hers Health in a report on Thursday, March 6th. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Piper Sandler boosted their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Finally, Needham & Company LLC raised their target price on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $37.31.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 64,338.5% during the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after buying an additional 8,364,000 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Hims & Hers Health by 29.0% in the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after buying an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after acquiring an additional 4,145,305 shares during the last quarter. Finally, State Street Corp grew its stake in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after acquiring an additional 206,078 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.